Cell therapy's poster child: Chimeric antigen receptor T cell therapy / 生物工程学报
Chinese Journal of Biotechnology
; (12): 2339-2349, 2019.
Article
em Zh
| WPRIM
| ID: wpr-781634
Biblioteca responsável:
WPRO
ABSTRACT
Chimeric antigen receptor T (CAR-T) cell therapy, which adoptively transfers engineered T cells expressing synthetic receptors to target specific antigens, has achieved great clinical success in treating hematological malignancies. Though FDA has approved two CAR-T products, CAR-T therapy can cause some side effects, such as cytokine release syndrome (CRS), neurotoxicity and B cell aplasia. Meanwhile, lacking tumor specific antigen and the suppressive tumor environment limit the efficacy of CAR-T therapy in solid tumor. This review focuses on the structural components, clinical applications and synthetic biology approaches on CAR-T cell design, and summarizes the challenges and perspectives of CAR-T therapy as a revolutionary cancer immunotherapy.
Palavras-chave
Texto completo:
1
Índice:
WPRIM
Assunto principal:
Receptores de Antígenos de Linfócitos T
/
Linfócitos T
/
Imunoterapia Adotiva
/
Terapia Baseada em Transplante de Células e Tecidos
/
Receptores de Antígenos Quiméricos
/
Imunoterapia
Limite:
Child
/
Humans
Idioma:
Zh
Revista:
Chinese Journal of Biotechnology
Ano de publicação:
2019
Tipo de documento:
Article